will cease operations on May 31, 2024. It has been our pleasure to join you on your health journey for the past 30 years. For more info, click here.


Information, Symptoms, Treatments and Resources


Alzheimer's Disease: Current Concepts & Future Directions



  1. Alzheimer’s Association. 2012 Alzheimer’s Disease Facts and Figures, Alzheimer’s & Dementia.; 8: 131-168.
  2. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 2009; 461:916-922.
  3. Verghese PB, Castellano JM, and Holtzman DM. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurology. 2011, 10:241-252.
  4. Mayeux R. Clinical practice. Early Alzheimer’s disease. N Engl J Med. 2010; 362:2194-2201.
  5. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7:263-269.
  6. Galvin JE, Roe CM, Xiong C, Morris JC. Validity and reliability of the AD8 informant interview in dementia. Neurology. 2006; 67:1942-1948.
  7. Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, Ensrud KE, Ancoli-Israel S, Stone KL. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011; 306:613-619.
  8. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiat Res. 1975; 12:189–198.
  9. Katzman R, Brown T, Fukd P, Peck A, Schechter R, Shimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiat. 1983; 140:734-739.
  10. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment (MoCA©): A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc. 2005; 53:695–699.
  11. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56:1143-1153.
  12. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Therapy. 2010; 32:1234-1251.
  13. Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia. The Cochrane Database of Systematic Reviews. 2005; Issue 3. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub4.
  14. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer’s disease: the Aβ target at a crossroads. Expert Opin Biol Ther. 2011; 11:679-686.
  15. Ghosh AK, Brindisi M, Tang J. Developing β-secretase inhibitors for treatment of Alzheimer’s disease. J Neurochem. 2012; 120 Suppl 1:71-83.
  16. Wolfe MS. γ-Secretase inhibitors and modulators for Alzheimer’s disease. J Neurochem. 2012; 120 Suppl 1:89-98.
  17. Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ. Et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012; 2:975-984.
  18. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer’s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011; 26 Suppl 3:321-329.
  19. Haydar SN, Dunlop J. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer’s disease. Curr Top Med Chem. 2010; 10:144-152.
  20. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012; 69:29-38.


Disclosure: None reported.


See also:


Explore More In Our Hep C Learning Center
image description
What Is Hepatitis C?
Learn about this treatable virus.
image description
Diagnosing Hepatitis C
Getting tested for this viral infection.
image description
Just Diagnosed? Here’s What’s Next
3 key steps to getting on treatment.
image description
Understanding Hepatitis C Treatment
4 steps to getting on therapy.
image description
Your Guide to Hep C Treatments
What you need to know about Hep C drugs.
image description
Managing Side Effects of Treatment
How the drugs might affect you.
image description
Making Hep C Treatment a Success
These tips may up your chances of a cure.